FY2024 EPS Estimates for Merus Decreased by Analyst (NASDAQ:MRUS)

Merus (NASDAQ:MRUS) – Investment analysts at Leerink Partnrs decreased their FY2024 earnings per share (EPS) estimates for shares of Merus in a report issued on Wednesday, April 24th. Leerink Partnrs analyst A. Berens now expects that the biotechnology company will earn ($3.66) per share for the year, down from their prior forecast of ($3.54). The consensus estimate for Merus’ current full-year earnings is ($3.31) per share. Leerink Partnrs also issued estimates for Merus’ Q4 2024 earnings at ($1.09) EPS, FY2025 earnings at ($4.16) EPS and FY2026 earnings at ($0.84) EPS.

Merus (NASDAQ:MRUS) last announced its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.38). The firm had revenue of $8.94 million during the quarter, compared to the consensus estimate of $10.43 million. Merus had a negative net margin of 352.56% and a negative return on equity of 50.61%.

MRUS has been the subject of a number of other research reports. William Blair reaffirmed an “outperform” rating on shares of Merus in a research report on Monday, April 22nd. StockNews.com cut Merus from a “hold” rating to a “sell” rating in a research report on Monday, March 4th. Truist Financial initiated coverage on Merus in a research report on Thursday, March 28th. They issued a “buy” rating and a $69.00 price objective for the company. HC Wainwright increased their price objective on Merus from $48.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $66.00 price objective on shares of Merus in a research report on Thursday, April 11th. One investment analyst has rated the stock with a sell rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, Merus presently has a consensus rating of “Moderate Buy” and an average target price of $56.33.

Merus Stock Performance

Shares of NASDAQ MRUS opened at $44.91 on Monday. The stock has a market cap of $2.64 billion, a price-to-earnings ratio of -14.77 and a beta of 1.10. The business has a 50 day simple moving average of $45.02 and a 200 day simple moving average of $34.34. Merus has a 52 week low of $18.21 and a 52 week high of $52.03.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Quadrant Capital Group LLC raised its holdings in shares of Merus by 37.7% in the fourth quarter. Quadrant Capital Group LLC now owns 1,253 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 343 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Merus by 64.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,120 shares of the biotechnology company’s stock valued at $58,000 after buying an additional 828 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Merus by 142.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,477 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 867 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in shares of Merus by 10.8% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 13,446 shares of the biotechnology company’s stock valued at $317,000 after buying an additional 1,310 shares during the last quarter. Finally, BluePath Capital Management LLC bought a new position in shares of Merus in the third quarter valued at about $33,000. 96.14% of the stock is currently owned by institutional investors and hedge funds.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.